IP Library Granted Patent US 11,197,836
Granted Patent B2
US 11,197,836 · App. 14/934,275 · Granted Dec 14, 2021

Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy

Inventors: William E. Fahl (Madison, WI); Arnold E. Ruoho (Madison, WI); Minesh Mehta (Sun Prairie, WI)
Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
A61K31/137A61K9/006A61K9/0014A61K45/06A61K47/10A61K47/12A61K47/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,197,836
App. No.
14/934,275
Granted
Dec 14, 2021
Kind
B2
Abstract

Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided.

Claims (15)

1. A method for reducing chemotherapy-induced alopecia in a patient treated or to be treated with a chemotherapeutic agent, comprising topically administering to the patient a preparation comprising a vasoconstrictor in a pharmaceutically acceptable delivery vehicle, wherein the vasoconstrictor comprises epinephrine, phenylephrine, norepinephrine, or a combination thereof, wherein the vasoconstrictor is administered to the patient in an amount effective to reduce the chemotherapy-induced alopecia, wherein the preparation is in a liquid form, and wherein the delivery vehicle comprises an aqueous alcohol mixture.

2. The method of claim 1 , wherein the vasoconstrictor comprises epinephrine.

3. The method of claim 1 , wherein the vasoconstrictor comprises phenylephrine.

4. The method of claim 1 , wherein the vasoconstrictor comprises norepinephrine.

5. A method for reducing chemotherapy-induced alopecia in a patient treated or to be treated with a chemotherapeutic agent, comprising topically administering to the patient a preparation comprising a vasoconstrictor in a pharmaceutically acceptable delivery vehicle, wherein the vasoconstrictor comprises epinephrine, phenylephrine, norepinephrine, or a combination thereof, wherein the vasoconstrictor is administered to the patient in an amount effective to reduce the chemotherapy-induced alopecia, wherein the delivery vehicle comprises an alcohol.

6. The method of claim 1 , wherein the patient is a patient treated or to be treated with cyclophosphamide.

7. The method of claim 1 , wherein the delivery vehicle comprises at least 10% alcohol.

8. The method of claim 1 , wherein the delivery vehicle comprises at least 55% alcohol.

9. The method of claim 1 , wherein the epinephrine, the phenylephrine, the norepinephrine, or the combination thereof comprises an epinephrine salt, a phenylephrine salt, a norepinephrine salt, or a combination thereof.

10. A method for reducing chemotherapy-induced alopecia in a patient treated or to be treated with a chemotherapeutic agent, comprising topically administering to the patient a preparation comprising a vasoconstrictor in a pharmaceutically acceptable delivery vehicle, wherein the vasoconstrictor comprises epinephrine, phenylephrine, norepinephrine, or a combination thereof, wherein the vasoconstrictor is administered to the patient in an amount effective to reduce the chemotherapy-induced alopecia.

11. The method of claim 10 , wherein the epinephrine, the phenylephrine, the norepinephrine, or the combination thereof comprises an epinephrine salt, a phenylephrine salt, a norepinephrine salt, or a combination thereof.

12. The method of claim 10 , wherein the vasoconstrictor comprises epinephrine.

13. The method of claim 10 , wherein the vasoconstrictor comprises phenylephrine.

14. The method of claim 10 , wherein the vasoconstrictor comprises norepinephrine.

15. The method of claim 10 , wherein the patient is a patient treated or to be treated with cyclophosphamide.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 16, 2018
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046173/0119 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2015
From: FAHL, WILLIAM E.; RUOHO, ARNOLD E.; MEHTA, MINESH P.
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 037089/0526 →
Continuity (5)
Continuation 13550662 · Jul 17, 2012
Continuation 13106293 · May 12, 2011
Division 11471047 · Jun 19, 2006
Provisional Application 60691571 · Jun 17, 2005
Related Publication 20160136113A1 · May 19, 2016